Celcuity (CELC) to Release Quarterly Earnings on Thursday

Celcuity (NASDAQ:CELC) is anticipated to post its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Celcuity to announce earnings of ($1.16) per share and revenue of $4.42 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.10. On average, analysts expect Celcuity to post $-4 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Celcuity Stock Down 2.1%

Celcuity stock opened at $90.79 on Tuesday. The business has a fifty day moving average of $93.93 and a two-hundred day moving average of $108.99. The company has a quick ratio of 12.31, a current ratio of 12.31 and a debt-to-equity ratio of 6.04. The firm has a market cap of $4.43 billion, a P/E ratio of -23.28 and a beta of 0.21. Celcuity has a twelve month low of $44.42 and a twelve month high of $151.02.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Macquarie Infrastructure set a $160.00 price target on shares of Celcuity in a research note on Thursday, May 28th. Guggenheim reiterated a “buy” rating on shares of Celcuity in a research note on Wednesday, June 3rd. Citizens Jmp boosted their price objective on shares of Celcuity from $160.00 to $177.00 and gave the company a “market outperform” rating in a report on Wednesday, July 15th. Wells Fargo & Company cut their target price on Celcuity from $183.00 to $166.00 and set an “overweight” rating on the stock in a research report on Wednesday, June 3rd. Finally, Wall Street Zen lowered Celcuity from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $155.18.

Institutional Trading of Celcuity

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets boosted its stake in shares of Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after acquiring an additional 1,167 shares during the last quarter. US Bancorp DE boosted its stake in Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after purchasing an additional 143 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Celcuity during the fourth quarter worth $42,000. Tower Research Capital LLC TRC grew its holdings in shares of Celcuity by 211.2% during the second quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock worth $74,000 after buying an additional 3,766 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Celcuity in the fourth quarter valued at about $101,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.